Proficio Capital Partners LLC Purchases Shares of 58,465 Hologic, Inc. (NASDAQ:HOLX)

Proficio Capital Partners LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 58,465 shares of the medical equipment provider’s stock, valued at approximately $4,215,000.

A number of other hedge funds have also recently bought and sold shares of HOLX. General Partner Inc. bought a new stake in Hologic in the 4th quarter valued at $26,000. Groupama Asset Managment boosted its holdings in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. Finally, Covestor Ltd raised its stake in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Down 1.5 %

HOLX opened at $62.30 on Wednesday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $13.98 billion, a PE ratio of 19.65, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1-year low of $62.28 and a 1-year high of $84.67. The firm has a 50-day moving average price of $68.77 and a two-hundred day moving average price of $75.64.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Morgan Stanley dropped their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday. Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of “Hold” and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.